Patogenitas Human Papillomavirus (Hpv) dalam Onkogenesis Kanker Serviks dan Pengembangan Vaksin Pencegahannya
DOI:
https://doi.org/10.33541/pro-life.v8i2.3206Keywords:
Human Papillomavirus (HPV), Cervical Cancer, VaccineAbstract
Human papillomavirus (HPV) is one of the main cause of various diseases, one of them is cervical cancer. Health problems caused by HPV infection, especially cervical cancer, are still a big burden for developing countries where cases of its infection are still very high and routine screening is still low. This article is based on literature studies on various research published online, especially on Google scholars, ScienceDirect, Scopus, Pubmed, and other scientific journals. Oncogenesis is a complex process and is very important in understanding the process of progression precancerous lesions to malignancy. Prevention of cervical cancer can be done by various efforts. HPV prophylactic vaccine and routine screening are the main modalities that have shown contribution to reduce morbidity and mortality of HPV infection in developed countries. Knowledge about oncogenesis process and the development of HPV prophylactic vaccines will greatly impact the prevention and reduction of cervical cancer in Indonesia.
References
Bonanni P, Boccalini S, & Bechini A. 2009. Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence. Vaccine, 27:A46–A53.
Bonnez W. 2007. Human papillomavirus vaccine-recent results and future developments. Curr Opin Pharmacol, 7(5): 470-477.
Borruto F & De Ridder M. 2012. HPV and cervical cancer achievement in prevention and the future prospect. New York: Springer Science Business Media.
Cheng, L, Wang Y, & Du J. 2020. Human papillomavirus vaccine: an update review. Vaccines. 8(3):391.
Closson K, Karim ME, Sadarangani M, Naus M, Ogilvie GS, & Donken R. 2020. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey- based cross-sectional analysis. Vaccine, 38(52): 8396-8404.
Cohen PA, Jhingra A, Oaknin A, & Denny L. 2019. Cervical cancer. Lancet, 393:169–182.
Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT. 2010. In vivo mechanisms of vaccine- induced protection against HPV infection. Cell Host Microbe, 8(3): 260-270.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. 2006. Clinical Science, 110:525–541.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. 2012. Global burden of human papillomavirus and related diseases. Vaccine, 30(suppl. 5):F12– F23.
Frazer I. 2007, Correlating immunity with protection for HPV infection. Int J Infect Dis, vol.11, suppl.2, pp. S10-6.
Frazer IH. 2008. HPV vaccines and the prevention of cervical cancer. Update on Cancern Therapeutics, 3:43–48.
Gissmann L. 2009. HPV Vaccines: Preclinical Development. Archives of Medical Research, 40:466-470.
Huh WK, Roden RB. 2008. The future of vaccines for cervical cancer. Gynecol Oncol, 109:S48–S56.
International Agency for Research on Cancer, World Health Organization. 2018. Latest world cancer statistics. https://www.who.int/cancer/PRGlobo canFinal.pdf.
Juanda D & Kesuma H. 2015. Pemeriksaan merode IVA (inspeksi visual asam asetat) untuk pencegahan kanker serviks. Jurnal Kedokteran dan Kesehatan, 2(2):169 – 174.
Lowy DR & Schiller JT. 2012. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila), 5(1): 18 – 23.
Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, & Wu TC. 2012. Emerginghuman papillomavirus vaccines. Expert Opin Emerg Drugs, 17(4):469-492.
Morshed K, Polz-Gruszka D, Szymanski M, Polz-Dacewicz M. 2014. Human papillomavirus (HPV) – structure, epidemiology and pathogenesis. Otolaryngol Pol, 68: 213-219.
Moscicki AB. 2008. HPV Vaccines: Today and in the Future. J Adolesc Health, 43(4 suppl): S26–S40.
Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. 2012. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine, 30(5): F24–33.
Nayereh KG & Khadem G. 2012. Preventive and therapeutic vaccine against human papillomaviruses associated cervical cancers. Iran J Basic Med Sc, 15(1): 585-601.
Oyervides-Muñoz MA, Perez Maya AA, Rodriguez-Gutierrez HF, Gomez- Macias GS, Fajardo-Ramiorez OR, Trevino V, Barrera-Saldana HA, & Garza-RodriguezML. 2018. Understanding the HPV integration and its progression to cervical cancer. Infect Genet Evol, 61: 134–144.
Paavonen J. 2007. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int. J Infect Dis, 11: S3-S9. Petry KU. 2014. HPV and cervical cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 74(244):59-62.
Stanley M. 2008. Immunobiology of HPV and HPV vaccines. Gynecol Oncol, 109:S15-S21.
Stanley M. 2010. Pathology and epidemiology of HPV infection in females. Gynecol Oncol, 117 (2suppl): S5-10.
Stanley M, Lowy DR, & Frazer I. 2006. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine, 24(S3):106-113.
Steben M, Duarte-Franco E. 2007. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol, 107(2 suppl): S2–S5.
Thomison 3rd J, Thomas LK, Shroyer KR. 2008. Human papillomavirus: molecular and cytology/histology aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol, 39(2): 154-166.
Villa A, Patton LL, Giuliano AR, Estrich CG, Pehlke SC, O’Brien KK, Lipman RD, Araujo MWB. 2020. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines Umbrella review of systematic reviews. J Am Dent Assoc, 151(4):245-254.
Wang JW, Roden RBS. 2013. Virus-like particles for the prevention of human papillomavirus associated malignancies. Expert Rev Vaccines, 12(2):151-156.
Wang R, Pa NW, Jin L, Huang W, Li Y, Wu D, Gao C, Ma D, Liao S. 2020,
Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett, 471:88– 102.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Desy Ariani Gultom
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
.svg_.png){kind=logo}
